TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07929480: A Phase 1/2a, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KL002, an AAV9 Gene Therapy, in Subjects With Parkinson's Disease

Sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd. · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,520,620

Rescue Site Savings

+$6,958,780

Unlock Full NCT07929480 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07929480 Rescue Dossier →